Published in Invest Ophthalmol Vis Sci on August 01, 2004
Influence of drug solubility and lipophilicity on transscleral retinal delivery of six corticosteroids. Drug Metab Dispos (2011) 1.48
Nanomedicines for back of the eye drug delivery, gene delivery, and imaging. Prog Retin Eye Res (2013) 1.06
Modeling of corneal and retinal pharmacokinetics after periocular drug administration. Invest Ophthalmol Vis Sci (2008) 0.98
Examination of penetration routes and distribution of ionic permeants during and after transscleral iontophoresis with magnetic resonance imaging. Int J Pharm (2006) 0.97
Biocompatibility and biodegradation studies of subconjunctival implants in rabbit eyes. PLoS One (2011) 0.94
In vivo assessment of aqueous humor dynamics upon chronic ocular hypertension and hypotensive drug treatment using gadolinium-enhanced MRI. Invest Ophthalmol Vis Sci (2014) 0.90
Transscleral iontophoretic and intravitreal delivery of a macromolecule: study of ocular distribution in vivo and postmortem with MRI. Exp Eye Res (2008) 0.89
MRI in ocular drug delivery. NMR Biomed (2008) 0.84
Contribution of saccadic motion to intravitreal drug transport: theoretical analysis. Pharm Res (2011) 0.82
In vivo ocular fluorophotometry: delivery of fluoresceinated dextrans via transscleral diffusion in rabbits. Invest Ophthalmol Vis Sci (2011) 0.81
Examination of barriers and barrier alteration in transscleral iontophoresis. J Pharm Sci (2008) 0.81
Spatiotemporal quantification of local drug delivery using MRI. Comput Math Methods Med (2013) 0.80
Biomedical Imaging in Implantable Drug Delivery Systems. Curr Drug Targets (2015) 0.78
Ocular delivery of pRNA nanoparticles: distribution and clearance after subconjunctival injection. Pharm Res (2013) 0.78
Ocular pharmacokinetic study of a corticosteroid by 19F MR. Exp Eye Res (2010) 0.77
Ocular pharmacokinetic study using T₁ mapping and Gd-chelate- labeled polymers. Pharm Res (2011) 0.77
Distribution of Triamcinolone Acetonide after Intravitreal Injection into Silicone Oil-Filled Eye. Biomed Res Int (2016) 0.75
MRI study of subconjunctival and intravitreal injections. J Pharm Sci (2012) 0.75
Episcleral clearance of sodium fluorescein from a bioerodible sub-tenon's implant in the rat. Exp Eye Res (2010) 0.75
Trans-scleral permeability of Oregon green 488. J Ocul Pharmacol Ther (2008) 0.75
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol (2005) 12.88
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol (2005) 9.72
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res (2008) 5.34
Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol (2011) 3.63
Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization. Invest Ophthalmol Vis Sci (2003) 3.04
Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci (2011) 2.53
The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res (2009) 2.25
Angiophagy prevents early embolus washout but recanalizes microvessels through embolus extravasation. Sci Transl Med (2014) 2.11
The involvement of sequence variation and expression of CX3CR1 in the pathogenesis of age-related macular degeneration. FASEB J (2004) 2.04
Stability of alemtuzumab solutions at room temperature. Am J Health Syst Pharm (2013) 2.03
Serum inflammatory markers in diabetic retinopathy. Invest Ophthalmol Vis Sci (2005) 1.92
VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. Proc Natl Acad Sci U S A (2009) 1.91
Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J Immunother (2004) 1.77
Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res (2006) 1.67
Detecting response of rat C6 glioma tumors to radiotherapy using hyperpolarized [1- 13C]pyruvate and 13C magnetic resonance spectroscopic imaging. Magn Reson Med (2010) 1.65
Monocyte activation in patients with age-related macular degeneration: a biomarker of risk for choroidal neovascularization? Arch Ophthalmol (2004) 1.57
A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies. Blood (2013) 1.56
Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br J Haematol (2005) 1.47
Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes. Invest Ophthalmol Vis Sci (2011) 1.46
Bone marrow-derived progenitor cells contribute to experimental choroidal neovascularization. Invest Ophthalmol Vis Sci (2003) 1.32
The long-term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow-up study. Ophthalmology (2003) 1.30
Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem (2006) 1.29
The remediation of heavy metals contaminated sediment. J Hazard Mater (2008) 1.25
Genome-wide interrogation identifies YAP1 variants associated with survival of small-cell lung cancer patients. Cancer Res (2010) 1.25
Age as an independent risk factor for severity of experimental choroidal neovascularization. Invest Ophthalmol Vis Sci (2002) 1.23
MR assessment of changes of tumor in response to hyperbaric oxygen treatment. Magn Reson Med (2006) 1.21
Biodegradable implants for sustained drug release in the eye. Pharm Res (2010) 1.20
A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide. Exp Eye Res (2005) 1.18
Transport barriers in transscleral drug delivery for retinal diseases. Ophthalmic Res (2007) 1.17
Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Invest Ophthalmol Vis Sci (2010) 1.17
FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye. Mol Vis (2009) 1.16
Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res (2002) 1.15
SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies. Clin Cancer Res (2011) 1.14
Vitreous VEGF clearance is increased after vitrectomy. Invest Ophthalmol Vis Sci (2009) 1.13
Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res (2010) 1.11
CO2-induced ion and fluid transport in human retinal pigment epithelium. J Gen Physiol (2009) 1.11
Regulation of estrogen receptors and MMP-2 expression by estrogens in human retinal pigment epithelium. Invest Ophthalmol Vis Sci (2003) 1.10
Central visual function and the NEI-VFQ-25 near and distance activities subscale scores in people with type 1 and 2 diabetes. Am J Ophthalmol (2005) 1.10
Reduction of CpG-induced arthritis by suppressive oligodeoxynucleotides. Arthritis Rheum (2002) 1.08
Genetic variation in an miRNA-1827 binding site in MYCL1 alters susceptibility to small-cell lung cancer. Cancer Res (2011) 1.08
Safety and pharmacokinetics of a preservative-free triamcinolone acetonide formulation for intravitreal administration. Retina (2006) 1.08
Nonlethal oxidant injury to human retinal pigment epithelium cells causes cell membrane blebbing but decreased MMP-2 activity. Invest Ophthalmol Vis Sci (2005) 1.08
Treatment of experimental anterior and intermediate uveitis by a dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci (2011) 1.06
Fluorescein angiographic findings in primary intraocular lymphoma. Retina (2002) 1.05
Mapping of the neonatal Fc receptor in the rodent eye. Invest Ophthalmol Vis Sci (2008) 1.04
Sarcoidosis in chronic granulomatous disease. Pediatrics (2006) 1.04
Quantitative enumeration of vascular smooth muscle cells and endothelial cells derived from bone marrow precursors in experimental choroidal neovascularization. Exp Eye Res (2005) 1.04
Late outgrowth endothelial progenitor cells in patients with age-related macular degeneration. Invest Ophthalmol Vis Sci (2008) 1.02
Assessment of subconjunctival and intrascleral drug delivery to the posterior segment using dynamic contrast-enhanced magnetic resonance imaging. Invest Ophthalmol Vis Sci (2007) 1.02
Survival of retinal pigment epithelium after exposure to prolonged oxidative injury: a detailed gene expression and cellular analysis. Invest Ophthalmol Vis Sci (2004) 1.01
Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage. Bioconjug Chem (2011) 1.01
Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer (2010) 0.99
Novel ocular antihypertensive compounds in clinical trials. Clin Ophthalmol (2011) 0.99
Angiogenesis inhibition and choroidal neovascularization suppression by sustained delivery of an integrin antagonist, EMD478761. Invest Ophthalmol Vis Sci (2007) 0.99
A functional -77T>C polymorphism in XRCC1 is associated with risk of breast cancer. Breast Cancer Res Treat (2010) 0.98
A novel bioerodible deep scleral lamellar cyclosporine implant for uveitis. Invest Ophthalmol Vis Sci (2006) 0.98
Characterization of functional excision repair cross-complementation group 1 variants and their association with lung cancer risk and prognosis. Clin Cancer Res (2008) 0.98
Attachment site recognition and regulation of directionality by the serine integrases. Nucleic Acids Res (2013) 0.97
Pore diameter mapping using double pulsed-field gradient MRI and its validation using a novel glass capillary array phantom. J Magn Reson (2010) 0.97
Functional and structural analysis of the human SLO3 pH- and voltage-gated K+ channel. Proc Natl Acad Sci U S A (2012) 0.96
Serious ophthalmic pathology compromising vision in HCV/HIV co-infected patients treated with peginterferon alpha-2b and ribavirin. AIDS (2004) 0.96
Retracted Matrix metalloproteinase 9 expression and prognosis in colorectal cancer: a meta-analysis. Tumour Biol (2012) 0.95
Investigating the movement of intravitreal human serum albumin nanoparticles in the vitreous and retina. Pharm Res (2008) 0.95
An apolipoprotein E variant may protect against age-related macular degeneration through cytokine regulation. Environ Mol Mutagen (2006) 0.94
Conjunctival involvement with T-cell prolymphocytic leukemia: report of a case and review of the literature. Surv Ophthalmol (2004) 0.94
Characterization of two mouse models of metastatic pheochromocytoma using bioluminescence imaging. Cancer Lett (2011) 0.92
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves the survival of gastric cancer patients with ovarian metastasis and peritoneal dissemination. Tumour Biol (2012) 0.92
Mapping prefrontal circuits in vivo with manganese-enhanced magnetic resonance imaging in monkeys. J Neurosci (2008) 0.91
Transient decrease in tumor oxygenation after intravenous administration of pyruvate. Magn Reson Med (2011) 0.91
Drug elimination kinetics following subconjunctival injection using dynamic contrast-enhanced magnetic resonance imaging. Pharm Res (2007) 0.91
Study of ocular transport of drugs released from an intravitreal implant using magnetic resonance imaging. Ann Biomed Eng (2005) 0.90
Curcumin-supplemented diets increase superoxide dismutase activity and mean lifespan in Drosophila. Age (Dordr) (2012) 0.89
Heterogeneous UV/Fenton degradation of TBBPA catalyzed by titanomagnetite: catalyst characterization, performance and degradation products. Water Res (2012) 0.89
Nanoparticle-integrin antagonist C16Y peptide treatment of choroidal neovascularization in rats. J Control Release (2009) 0.89
The pharmacokinetics of rituximab following an intravitreal injection. Exp Eye Res (2005) 0.88